Literature DB >> 23509508

Dabigatran in atrial fibrillation: New kid on the block.

Timothy S Leung, Miriam Fradette, Ann Thompson, Sheri L Koshman.   

Abstract

Entities:  

Year:  2012        PMID： 23509508      PMCID： PMC3567542          DOI： 10.3821/145.2.cpj83

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN： 1715-1635


× No keyword cloud information.
  12 in total

1.  Newly identified events in the RE-LY trial.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; Paul A Reilly; Lars Wallentin
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

Review 2.  Stroke prevention and treatment.

Authors:  James D Marsh; Salah G Keyrouz
Journal:  J Am Coll Cardiol       Date:  2010-08-24       Impact factor: 24.094

Review 3.  The evolving field of stroke prevention in patients with atrial fibrillation.

Authors:  Michael D Ezekowitz; Timothy H Aikens; Annamarie Brown; Zack Ellis
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

Review 4.  Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.

Authors:  Wolfgang G Eisert; Norbert Hauel; Joachim Stangier; Wolfgang Wienen; Andreas Clemens; Joanne van Ryn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-07-29       Impact factor: 8.311

Review 5.  Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.

Authors:  Fazeel M Siddiqui; Adnan I Qureshi
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

Review 6.  Atrial fibrillation and stroke management: present and future.

Authors:  David R Holmes
Journal:  Semin Neurol       Date:  2011-01-04       Impact factor: 3.420

7.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.

Authors:  John A Cairns; Stuart Connolly; Sean McMurtry; Michael Stephenson; Mario Talajic
Journal:  Can J Cardiol       Date:  2011 Jan-Feb       Impact factor: 5.223

8.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

Review 9.  Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature.

Authors:  G Dolan; L A Smith; S Collins; J M Plumb
Journal:  Curr Med Res Opin       Date:  2008-04-09       Impact factor: 2.580

10.  Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care.

Authors:  Tammy J Bungard; Leslie Gardner; Stephen L Archer; Peter Hamilton; Bruce Ritchie; Wayne Tymchak; Ross T Tsuyuki
Journal:  Open Med       Date:  2009-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.